DekaBank Deutsche Girozentrale Cuts Holdings in Encompass Health Corporation (NYSE:EHC)

DekaBank Deutsche Girozentrale cut its holdings in Encompass Health Corporation (NYSE:EHC - Free Report) by 39.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,605 shares of the company's stock after selling 3,588 shares during the quarter. DekaBank Deutsche Girozentrale's holdings in Encompass Health were worth $560,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. OneDigital Investment Advisors LLC bought a new stake in Encompass Health during the 1st quarter valued at $263,000. GAMMA Investing LLC boosted its position in Encompass Health by 21.5% during the first quarter. GAMMA Investing LLC now owns 2,366 shares of the company's stock valued at $240,000 after purchasing an additional 419 shares in the last quarter. Cambridge Investment Research Advisors Inc. grew its stake in Encompass Health by 30.1% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 9,597 shares of the company's stock valued at $972,000 after purchasing an additional 2,218 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in Encompass Health by 6.7% in the first quarter. Sequoia Financial Advisors LLC now owns 2,727 shares of the company's stock worth $276,000 after purchasing an additional 172 shares in the last quarter. Finally, Fifth Third Bancorp lifted its position in shares of Encompass Health by 88.7% during the first quarter. Fifth Third Bancorp now owns 4,290 shares of the company's stock valued at $434,000 after buying an additional 2,017 shares during the last quarter. 97.25% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Encompass Health news, insider Elissa Joy Charbonneau sold 4,279 shares of Encompass Health stock in a transaction on Tuesday, May 6th. The shares were sold at an average price of $116.61, for a total value of $498,974.19. Following the completion of the transaction, the insider owned 11,958 shares of the company's stock, valued at approximately $1,394,422.38. The trade was a 26.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP John Patrick Darby sold 10,000 shares of Encompass Health stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the completion of the transaction, the executive vice president directly owned 79,710 shares of the company's stock, valued at $9,149,910.90. The trade was a 11.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 132,663 shares of company stock valued at $16,034,082 over the last 90 days. Insiders own 2.00% of the company's stock.

Encompass Health Stock Performance

Shares of NYSE EHC traded up $0.36 during midday trading on Thursday, reaching $110.28. The company had a trading volume of 1,155,220 shares, compared to its average volume of 731,885. The business's 50-day simple moving average is $119.18 and its 200 day simple moving average is $106.70. The stock has a market cap of $11.12 billion, a P/E ratio of 22.78, a P/E/G ratio of 2.23 and a beta of 0.88. Encompass Health Corporation has a 1 year low of $82.74 and a 1 year high of $123.13. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.81.

Encompass Health (NYSE:EHC - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $1.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.19 by $0.18. The business had revenue of $1.46 billion during the quarter, compared to analysts' expectations of $1.43 billion. Encompass Health had a net margin of 8.97% and a return on equity of 17.63%. The business's quarterly revenue was up 10.6% on a year-over-year basis. During the same quarter last year, the company posted $1.12 earnings per share. On average, analysts forecast that Encompass Health Corporation will post 4.8 earnings per share for the current fiscal year.

Encompass Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, July 15th. Investors of record on Tuesday, July 1st were issued a dividend of $0.17 per share. The ex-dividend date of this dividend was Tuesday, July 1st. This represents a $0.68 annualized dividend and a dividend yield of 0.62%. Encompass Health's dividend payout ratio (DPR) is presently 14.05%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. KeyCorp boosted their price objective on shares of Encompass Health from $122.00 to $135.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 27th. Stephens raised Encompass Health from an "overweight" rating to a "strong-buy" rating and set a $135.00 price target on the stock in a research report on Thursday, June 5th. UBS Group raised their price objective on Encompass Health from $117.00 to $130.00 and gave the stock a "buy" rating in a research report on Monday, April 28th. Barclays upped their target price on Encompass Health from $118.00 to $129.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Finally, Royal Bank Of Canada raised their price target on Encompass Health from $110.00 to $125.00 and gave the stock an "outperform" rating in a report on Monday, April 28th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $131.50.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.